A key player in the local pharmaceutical industry, the Philippine affiliate is among the top five pharmaceutical companies in the Philippines. It is one of the largest affiliates of the sanofi-aventis Group in Southeast Asia, with a strong and dedicated workforce of about 700, all committed to the service of a cause that really matters… health.

The Philippine affiliate is driven by its mission to improve the quality of life and well-being of all its stakeholders by offering innovative medicines and vaccines, quality generics and consumer health products, delivered by highly empowered professionals who conduct business ethically, in partnership with the medical community. 

Sanofi-aventis is the world’s 3rd leading pharmaceutical group. It is ranked 1st in the pharmaceutical industry in Europe and in the BRIC-M (Brazil, Russia, India, China and Mexico).

The Group operates in more than 100 countries, with nearly 100,000 employees. It has more than 19,300 scientists working in 28 research centers in three continents to create innovative therapeutic treatments.

The Group’s operational headquarters are located in Paris, France. 

Sanofi-aventis provides innovative therapeutic solutions to fight disease in seven major areas of expertise: thrombosis, cardiovascular diseases, diabetes, vaccines, oncology, central nervous system disorders and internal medicine.

It also holds strong position in consumer health and is strengthening the development of its generic product range. 

Sanofi-aventis has one of the richest and most innovative portfolios of compounds in the whole pharmaceutical industry. Its state-of-the-art research is one of the best R&D organizations in the world.

Sanofi-aventis dedicates its research to finding solutions for future therapeutic challenges. Its rich R&D pipeline has a large number of compounds and vaccines under development, with 47 products in advanced stages of clinical investigation (phases IIb and III).

The company invested 4.5 billion euros in R&D in 2007, the 3rd largest in the pharmaceutical industry. 

To improve access to quality and affordable medicines to millions of Filipinos, sanofi-aventis Philippines launched its generics arm, Winthrop Pharmaceuticals Philippines, Inc., in October 2007.

Built on the enduring strengths of the sanofi-aventis Group, Winthrop is driven by a commitment to actively and responsively contribute to the reduction of healthcare cost. The Winthrop brand is in response to the public clamor for more accessible, affordably-priced quality medicines.

Winthrop addresses major health needs in therapeutic areas such as metabolic, cardiology, and thrombosis. It guarantees the highest standards of quality not only in terms of product efficacy and safety, but also in terms of strict manufacturing quality control. 

Sanofi-aventis concentrates on seven therapeutic fields where it has developed world-renowned expertise. It is constantly focused on confronting disease, with one overriding aim: to save lives.

The group also dedicates its research to finding solutions to public health challenges like malaria, tuberculosis, and viral endemic diseases, such as avian influenza.

To protect human health and combat disease throughout the world, sanofi-aventis continues to mobilize its resources to discover and develop innovative, effective and safe medicines, with just one end in view: patient health. 

Access to Medicines is a central element in the Group’s global strategy. An Access to Medicines Division coordinates and implements the sanofi-aventis Group’s initiatives in the fight against certain diseases which represent major public health problems in which the Group has real acknowledged expertise.

The mission of the Access to Medicines program is to produce medicines in strict compliance with the Group’s quality standards and make them available to underprivileged populations at prices adjusted according to patient category within the framework of “no profit, no loss” policy.

Access to Medicines is focused on six major therapeutic areas: malaria, tuberculosis, sleeping sickness, leishmaniasis, epilepsy and vaccines. 

Sanofi-aventis Philippines is committed to make available innovative therapeutic medicines vital in the treatment of major diseases. With the Group’s breakthrough products and major advances in research, the Philippine affiliate hopes to contribute in a significant way to the improvement of the health and well-being of all Filipinos.

For more information about sanofi-aventis worldwide, visit www.sanofi-aventis.com.